Omalizumab safety in pregnancy

Francesca Levi-Schaffer; David Mankuta

doi:10.1016/j.jaci.2019.11.018

Omalizumab safety in pregnancy

Francesca Levi-Schaffer^*, David Mankuta

^*Corresponding author for this work

School of Pharmacy

Research output: Contribution to journal › Editorial

7 Scopus citations

Original language	English
Pages (from-to)	481-483
Number of pages	3
Journal	Journal of Allergy and Clinical Immunology
Volume	145
Issue number	2
DOIs	https://doi.org/10.1016/j.jaci.2019.11.018
State	Published - Feb 2020

Bibliographical note

Funding Information:
We acknowledge the assistance of Fidan Rahimli Alekberli, MD, in discussions of the manuscript and the literature search. Dr Levi-Schaffer is affiliated with the Adolph and Klara Brettler Center at the Hebrew University. F.L.-S.’s research is funded partly by the Israel Science Foundation, Rosetrees Trust (United Kingdom), Aimwell Charitable Trust (United Kingdom), the United States–Israel Binational Science Foundation (BSF), and the Israel Ministry of Science and Technology.

Keywords

Omalizumab
drug safety
fetal malformations
placental transfer
pregnancy
preterm delivery
thrombocytopenia

Access to Document

10.1016/j.jaci.2019.11.018

Cite this

@article{301d20f30291491fb4bc61094e2c4208,

title = "Omalizumab safety in pregnancy",

keywords = "Omalizumab, drug safety, fetal malformations, placental transfer, pregnancy, preterm delivery, thrombocytopenia",

author = "Francesca Levi-Schaffer and David Mankuta",

note = "Funding Information: We acknowledge the assistance of Fidan Rahimli Alekberli, MD, in discussions of the manuscript and the literature search. Dr Levi-Schaffer is affiliated with the Adolph and Klara Brettler Center at the Hebrew University. F.L.-S.{\textquoteright}s research is funded partly by the Israel Science Foundation, Rosetrees Trust (United Kingdom), Aimwell Charitable Trust (United Kingdom), the United States–Israel Binational Science Foundation (BSF), and the Israel Ministry of Science and Technology.",

year = "2020",

month = feb,

doi = "10.1016/j.jaci.2019.11.018",

language = "אנגלית",

volume = "145",

pages = "481--483",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Omalizumab safety in pregnancy

AU - Levi-Schaffer, Francesca

AU - Mankuta, David

N1 - Funding Information: We acknowledge the assistance of Fidan Rahimli Alekberli, MD, in discussions of the manuscript and the literature search. Dr Levi-Schaffer is affiliated with the Adolph and Klara Brettler Center at the Hebrew University. F.L.-S.’s research is funded partly by the Israel Science Foundation, Rosetrees Trust (United Kingdom), Aimwell Charitable Trust (United Kingdom), the United States–Israel Binational Science Foundation (BSF), and the Israel Ministry of Science and Technology.

PY - 2020/2

Y1 - 2020/2

KW - Omalizumab

KW - drug safety

KW - fetal malformations

KW - placental transfer

KW - pregnancy

KW - preterm delivery

KW - thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=85078685251&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2019.11.018

DO - 10.1016/j.jaci.2019.11.018

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.editorial???

C2 - 31778706

AN - SCOPUS:85078685251

SN - 0091-6749

VL - 145

SP - 481

EP - 483

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 2

ER -

Omalizumab safety in pregnancy

Bibliographical note

Keywords

Access to Document

Other files and links

Cite this